Drugs / EBA-175 RII-NG
EBA-175 RII-NG
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01026246 | Jun 2010 → Mar 2012 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00347555 | May 2006 → Apr 2008 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBA-175 RII-NG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01026246 ↗ |
| Known as | erythrocyte-binding antigen 175 kDA region II-nonglycosylated | “Researchers propose to conduct a Phase I dosage-escalating study to assess the safety and immunogenicity of 3 different dosages of erythrocyte-binding antigen 175 kDA region...” NCT01026246 ↗ |
| Modality | Vaccine | “This study is a phase I, double-blinded, placebo-controlled, dosage-escalation study of the safety and immunogenicity of EBA-175 RII-NG malaria vaccine administered intramuscularly.” NCT00347555 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT00347555 ↗ |